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OBJECTIVE — Because diabetes is the most frequent factor responsible for microvascular and
macrovascular disease, we investigated angiogenin serum levels within the diabetic patient group.
RESEARCH DESIGN AND METHODS — We investigated 49 patients who met the
criteria to be in the diabetic group. Forty nondiabetic patients were included in the control
group. We set A1C 7% as well-controlled diabetes. Serum angiogenin level was measured
using the enzyme-linked immunosorbent assay method.
RESULTS — Serum angiogenin levels of poorly controlled patients with type 2 diabetes were
signiﬁcantlylowerthanthoseofgroupwithwell-controlleddiabetes(361.23126.03ng/mlvs.
446.37134.10ng/ml;P0.001).Moreover,theywerecharacterizedbyasigniﬁcantlylonger
durationofthedisease(P0.006),higherBMI(P0.0003),andhighersystolicbloodpressure
(P  0.01). Levels of total cholesterol, triglycerides, LDL, and HDL were not signiﬁcantly
different in both groups.
CONCLUSIONS — Patients with poorly controlled type 2 diabetes (A1C 7%) have lower
angiogenin levels than patients with well-controlled diabetes.
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D
iabetesisassociatedwithangiopathy,
whichincreasestheriskofavarietyof
complications. To minimize the de-
gree of ischemic damage, collateral vessels
ofthelargearteriesaredeveloped.Thispro-
cess is, unfortunately, insufﬁcient in dia-
beticpatients,leadingtoathree-tofourfold
increase in mortality risk. Both coronary
vessel formation and capillary density are
poorer in patients with diabetes than in a
healthy control group (1,2).
Angiogenesis is a complex process reg-
ulatedbystimulatoryandinhibitoryfactors.
It is well established in research that the ex-
pression of different angiogenic growth fac-
tors are reduced in diabetes. On the other
hand,diabeticpatientswithcoronaryartery
disease exhibit higher levels of angiostatin
and endostatin (3). In the meantime, the
molecular angiogenic signaling pathways
inﬂuencing coronary collateral formation
remain poorly understood.
We have previously demonstrated that
the serum level of one of the angiogenic
growth factors, namely angiogenin, is re-
duced in diabetes (4). The present investi-
gation was designed to test the hypothesis
that the serum level of angiogenin depends
on glucose concentration control.
RESEARCH DESIGN AND
METHODS— A total of 49 consecu-
tivepatientswithtype2diabetesfromthe
Department of Family Medicine, Medical
UniversityofGdansk,admittedtotheDe-
partment of Ophtalmology for a routine
control were recruited between Septem-
ber and December 2009. They were di-
vided into two groups according to the
level of A1C (18 subjects with A1C 7%
and 31 subjects with A1C 7%). Patients
suffering from acute and chronic infec-
tions and neoplastic diseases were ex-
cluded. Diabetes was deﬁned according
to American Diabetes Association criteria
(5). All patients had blood glucose 7
mmol/l, and we set A1C 7% as well-
controlled diabetes. Serum angiogenin
levels were measured twice with the
ELISA Quantkine kit (R&D Systems,
Minneapolis, MN). A1C was evaluated by
the immunoturbidimetric method using
the Unimate 3 set (Hoffmann-La Roche,
Basel,Switzerland).Agroupof40healthy
age- and sex-matched individuals was
used as a control. They remained under
continuous supervision at The Family
Medicine Outpatient Clinic.
The results were analyzed using Sta-
tistica software, version 8 (Stat Soft Pol-
ska). The level of signiﬁcance was set at
P  0.05. Student t and the Kruskal-
Wallis ANOVA tests were performed as
standard.
RESULTS— Serum angiogenin levels
of poorly controlled patients with type 2
diabetes were signiﬁcantly lower than
those of the group with well-controlled
diabetes (P  0.001). Moreover, they
were characterized by a signiﬁcantly
longer duration of the disease and higher
BMIandsystolicbloodpressure.Levelsof
total cholesterol, triglycerides, LDL, and
HDL were not signiﬁcantly different from
those of the well-controlled patients (Ta-
ble 1).
The patients with A1C 7% suffered
signiﬁcantly more often from hyperten-
sion (P  0.003) and ischemic heart dis-
ease (P  0.004). However, there was no
signiﬁcant difference in the occurrence of
late complications of diabetes.
There were signiﬁcant differences be-
tween treatment regimes. The well-
controlled patients received sulfonylurea
signiﬁcantly more often (P  0.0007),
while the poorly controlled group was
treated mainly with insulin (P  0.002).
No signiﬁcant differences in statin and
ACE inhibitor treatment were observed.
The serum angiogenin level of the
healthy control group was signiﬁcantly
higher than that of the total diabetic pa-
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392.5  134.2 ng/ml; P  0.000017).
ANOVA and post hoc NIR Fisher test de-
tected signiﬁcant differences between
healthy subjects and patients with A1C
7% (472.57  146.30 ng/ml vs.
361.23  126.03 ng/ml; P  0.00002)
and within the two diabetic groups P 
0.03.
CONCLUSIONS — The rising preva-
lence of diabetes is leading to a signiﬁcant
increase in long-term diabetes complica-
tions such as retinopathy, nephropathy,
neuropathy, and ischemic heart disease,
which have a considerable impact on the
patients (6). The data available on the ef-
fect of hyperglycemia on the process of
angiogenesis are still limited. Numerous
authors have suggested that a high con-
centration of glucose causes endothelial
cell dysfunction (7,8). Weihrauch et al.
(9)indicatedthattheproductionofinhib-
itors of angiogenesis is an important
mechanism for the impairment of collat-
eral development observed during
hyperglycemia.
Angiogenin is an important and still
poorly investigated angiogenic growth
factor (10) that has a great inﬂuence on
the process of creation of new vessels.
When introduced into Balb/c mice in a
serum-induced angiogenesis test, the se-
rum angiogenin of diabetic patients
causesasigniﬁcantdecreaseinnewvessel
formation (4).
The present results conﬁrm the ﬁnd-
ings of our previous studies and indicate
thecorrelationbetweentheglycemiccon-
trolandtheinhibitionoftheserumangio-
geninlevel.Wediscoveredthattheserum
angiogenin level is markedly decreased in
patients with A1C 7% in comparison
with well-controlled patients and their
healthy counterparts. Furthermore,
poorly controlled patients had a higher
proportion of hypertension and ischemic
heart disease and greater BMI. These data
are comparable with the results of differ-
entobservationalstudies(11).Thelonger
the duration of diabetes, the poorer its
control and the lower the serum angioge-
nin level.
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Table 1—Basic parameters of well-controlled and poorly controlled diabetic groups
Parameter A1C  7% A1C  7% P value
n 18 31
Age (years) 66.22  12.34 66.29  8.91 0.8436
Weight (kg) 75.18  12.73 86.82  16.15 0.0127
BMI (kg/m
2) 26.56  3.37 32.05  6.07 0.0003
Systolic blood pressure (mmHg) 130.53  12.76 142.77  16.87 0.0127
Diastolic blood pressure (mmHg) 72.41  18.00 79.30  9.26 0.1054
Diabetes duration (years) 7.12  5.53 12.33  6.33 0.0068
A1C (%) 6.17  0.44 8.69  1.40 0.0000001
Angiogenin (ng/ml) 446.37  134.10 361.23  126.03 0.0308
Total cholesterol (mmol/l) 195.18  29.25 212.07  38.09 0.1263
LDL cholesterol (mmol/l) 118.81  23.87 127.48  35.80 0.3948
HDL cholesterol (mmol/l) 45.82  11.04 51.59  20.23 0.3,467
Triglycerides (mmol/l) 145.56  68.53 167.11 64.20 0.3055
Hypertension (%) 66.67 96.77 0.0037
Nephropathy (%) 5.56 6.45 0.8996
Retinopathy (%) 17.65 30.00 0.3507
Foot ulceration (%) 11.11 16.13 0.6285
Ischemic heart disease (%) 11.11 51.61 0.0046
ACE inhibitor (%) 52.94 80.00 0.0513
Statins (%) 29.41 51.72 0.1406
Sulphonylurea (%) 84.62 11.11 0.0007
Metformin (%) 53.85 22.22 0.1380
Insulin (%) 23.08 88.89 0.0024
Data are arithmetic means  SD or percentage of patients.
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